Jährlich findet das Deutsch-Österreich-Schweiz (D-A-CH) MDS Gruppen Treffen auf dem Campus der Universitätsklinikum statt. Hierbei kommen unsere Verbundpartner und Kooperationspartner zusammen, um die Ergebnisse ihrer Untersuchungen darzustellen. Im Fokus unserer Veranstaltung stehen vor allem neue Ergebnisse, Diskussionen hierzu und gleichwohl Ziele für das kommende Jahr. Dieser Austausch ist essentiell für klinische und wissenschaftliche Fragestellungen. So jährte sich das DACH Treffen im 2023 zum zwanzigsten mal. Das diesjährige Treffen ist am 17.9.2025 im Hörsaal 13a am UK Düsseldorf ab 9:30 Uhr.

Poster:

• P069: PROGNOSTIC IMPACT OF CYTOGENETIC CLONE SIZE IN PATIENTS WITH MDS – DATA OF THE GERMAN-AUSTRIAN-SUISSE MDS WORKING GROUP (Jan Bader)
• P072: UNVEILING THE IMPACT OF FIBROSIS: SIGNIFICANTLY SHORTER SURVIVAL IN MDS-F PATIENTS COMPARED TO HIGH-RISK SUBTYPES (Annika Kasprzak)
• P079: CLONAL-HEMATOPOIESIS-ASSOCIATED VARIANTS IN A HEREDITARY BREAST AND OVARIAN CANCER COHORT FROM DÜSSELDORF (AnnaMaria Cacic)
• P095: IMPACT OF PRIOR TREATMENTS ON THE CLINICAL ACTIVITY OF IMETELSTAT IN PATIENTS WITH TRANFUSION-DEPENDENT (TD), ERYTHROPOIESIS-STIMULATING AGENT (ESA) RELAPSED/REFRACTORY/INELIGIBLE LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) (Uwe Platzbecker…. Ulrich Germing…)
• P039: A COMPARISON OF PROGNOSTIC VARIABLES AND CYTOGENETIC ABERRATIONS IN 1590 PATIENTS WITH THERAPY-RELATED AND 4738 WITH PRIMARY MDS INCLUDING THE INFLUENCE OF TREATMENT IN MDS-PHASE (Andrea Kuendgen)

Vorträge

• RF012: COMPARISON OF TIME TO THERAPY INITIATION, THERAPEUTIC STRATEGIES AND SURVIVAL IN PATIENTS WITH MDS IB1, IB2 AND AML-MRC USING DATA OF THE DUESSELDORF REGISTRIES (Felicitas Schulz)
• MDS CLASSIFICATION IN 2025 (Ulrich Germing)

Vorträge:

• V125 Clinical and Molecular Characteristics of Patients with VEXAS Syndrome: First Results from the Multicenter German VEXAS-Registry (J.-A. Georgi)
• V366 Rapid FISH-panel analysis with 6 probes is reliable, fast and comprehensive tool for identification of MR-type AML-results of a prospective diagnostic dicendric trial (D. Haase)
• V1018: IWG and ELN response criteria are not suitable for patients with MDS or AML in clinical routine (D. Synkova-Popova)

Poster:

• P544: Complementary and alternative medicine (CAM) use in patients with myelodysplastic syndromes (MDS) and myelodysplastic/myeloproliferative (MDS/MPN) overlap syndromes (C. Strupp)
• P545 Oligomonocytic-CMML vs. „classical“ CMML: Differences in hematologic features and prognosis (A. Stratelmann)
• P548: AZALOX: A Phase Ib/II Study of Azacitidine in Combination with the Pan-Lysyl Oxidase Inhibitor PXS-5505 in Patients with higher-risk Myelodysplastic Neoplasma (MDS) in Chronic Myelomonocytic Leukemia (CMML) (A. Streuer)
• P549: Elevated ferritin is associated with genomic instability in myelodysplastic neoplasia (C. Ganster)
• 550: Systemic metabolic changes in plasma of patients with myelodysplastic neoplasms (E. Balaian)